GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians

Rhea-AI Summary

Genetic Technologies Limited (NASDAQ: GENE) has partnered with Melbourne's Siles Health to integrate the geneType Multi-Risk Test into their obstetrics and gynaecology practices. This initiative aims to enhance personalized patient care by identifying high-risk patients for various serious diseases.

Siles Health, treating over 15,000 patients each year, will incorporate genetic counseling services for actionable patient pathways. The geneType Multi-Risk Test assesses risks for diseases like breast and colorectal cancer. The partnership represents a key step in GENE's commercialization strategy, promising improved health outcomes for patients.

Positive

• Partnership with Siles Health provides access to a substantial patient base of over 15,000 annually.
• Introduction of dedicated in-house genetic counseling services enhances patient support and outcomes.
• The geneType Multi-Risk Test addresses risks of serious diseases, potentially increasing demand for GENE's services.

Negative

• None.

MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with Melbourne based Siles Health, a leading Obstetrics and Gynaecology practice, to implement geneType Multi-Risk Test as part of their commitment to remain at the forefront of contemporary personalised patient health care.

Siles Health, founded by leading Obstetrician and Gynaecologist, A/Prof. Charles Siles, operates nine (9) clinics across Victoria. A/Prof. Siles’ clinics specialise in obstetrics and gynaecology delivering a comprehensive range of personalised healthcare from screening to treatment for women.

Highlights:

• Siles Health treats over 15,000 patients annually
• Siles Health has a current active referral national network of more than 1,000 GPs
• Siles Health will provide a dedicated in-house genetic counselling service for all patients who are identified as high risk creating the most actionable patient pathways
• Siles Health will also support any referring physicians with dedicated genetic counselling support

The geneType Multi-Risk Test is a comprehensive solution that enables an understanding of a patient’s risk of developing a range of common serious diseases. The geneType Multi-Risk Test looks beyond inherited diseases and identifies sporadic (non inherited)¹ risk which can account for up to 85% of diagnosed cancers in diseases such as breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes. Over 212,400² individuals in Australia receive a diagnosis related to one of these six diseases annually.

GENE’s CEO, Simon Morriss, said, “Adoption of geneType Multi-Risk Test by Siles Health provides GENE with immediate access to an important and expanding group of patients with the opportunity to make a significant improvement in their health outcomes. This partnership also represents another significant milestone along our pathway to the successful commercialisation of geneType Multi-Risk Tests.”

A/Prof. Charles Siles, founder of Siles Health, noted, “geneType Multi-Risk Test is a critical risk identification tool to assist our practice to identify potentially high-risk patients and develop truly actionable, personalised, preventative health plans.”

¹ https://www.cancer.org/cancer/breast-cancer/about/how-does-breast-cancer-form.html
² https://www.canceraustralia.gov.au/impacted-cancer/what-cancer/cancer-australia-statistics, https://www.aihw.gov.au/reports/australias-health/diabetes, https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/about, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

Enquiries

Investor Relations
Justin Foord
Market Eye
M: +61 402 600 691
E: justin.foord@marketeye.com.au

About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com

About Siles Health

The four core areas where Siles Health offers the highest levels of patient care are Service, Research, People and Location. They take client service seriously with exceptionally trained staff to address the most complex situations. Our clients and the referring doctors feel confident their patients are receiving the best treatment available. Siles Health is at the forefront on advancements Research, treatment, and scanning techniques with the most cutting-edge technology. Encouraging clinical research to keep abreast of changes in best practice by contributing and monitoring with our associates nationally and internationally. Our People are experts at looking after clients and referring doctors with the right technical know-how, attitude and an understanding serving exceptional screening services across Melbourne and regional Victoria supported by a national counselling program. For more information, please visit https://www.sileshealth.com.au

FAQ

What is the significance of the partnership between GENE and Siles Health?

The partnership enables GENE to access a large patient base and enhance personalized healthcare through the geneType Multi-Risk Test.

How does the geneType Multi-Risk Test improve patient care?

It identifies risks for common serious diseases, allowing for personalized preventative health plans.

What types of diseases does the geneType Multi-Risk Test assess?

It assesses risks for diseases like breast cancer, colorectal cancer, and type 2 diabetes.

How many patients does Siles Health treat each year?

Siles Health treats over 15,000 patients annually.

What additional support does Siles Health offer to patients?

Siles Health provides dedicated in-house genetic counseling for high-risk patients and support for referring physicians.